title: Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia.
abstract: BACKGROUND
  To evaluate the efficacy and safety of intravitreal bevacizumab (Avastin) in the treatment of subretinal neovascularization (SRNV) secondary to type 2A idiopathic juxtafoveal telangiectasia (IJT).
  
  
  METHODS
  Intravitreal bevacizumab (1.25 mg/0.05 ml) was injected as primary treatment into six eyes of six patients with SRNV due to IJT in this nonrandomized, interventional case series. The best-corrected visual acuity (BCVA) was measured and the optical coherence tomography (OCT) and fundus fluorescein angiography (FFA) findings were examined before and after treatment. The patients were followed up for 3-6 months.
  
  
  RESULTS
  Pre-injection BCVA measured 20/400 to 20/120 (mean 20/200). After a mean follow-up of 4.2 months, post-injection BCVA measured 20/200 to 20/50 (mean 20/100). At last visit BCVA improved two or more lines in five eyes (83%) and remained the same in one eye (17%). The mean central foveal thickness improved from 263 microm (range, 165 to 393 microm) to 201 microm (range, 126 to 351 microm), representing an average reduction of 62 mum. Only one eye received more than one (2) bevacizumab injections. No significant complications were observed.
  
  
  CONCLUSIONS
  In this small series, intravitreal bevacizumab appears to be a safe and effective treatment for SRNV secondary to type 2A IJT.
authors.affiliation: Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi 110029, India. drsubratamandal@gmail.com
authors.forename: Subrata
authors.initials: S
authors.lastname: Mandal
authors.forename: Pradeep
authors.initials: P
authors.lastname: Venkatesh
authors.forename: Zahir
authors.initials: Z
authors.lastname: Abbas
authors.forename: Rajpal
authors.initials: R
authors.lastname: Vohra
authors.forename: Satpal
authors.initials: S
authors.lastname: Garg
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D015861:Retinal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D012171:Retinal Vessels / Q000473:pathology*; D013684:Telangiectasis / Q000145:classification / Q000150:complications / Q000188:drug therapy*; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab